The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Biotech stocks managed to carve out modest gains for the week ending April 8, defying the broader market weakness. The defensive nature of the stocks make them appealing in times of risk aversion.
Data readouts triggered some stock-specific reactions. Phio Pharmaceuticals, Inc. (NASDAQ:PHIO) was among the best performers for the week after reporting positive preclinical data on an RNAi therapeutic candidate meant to enhance the efficacy of anti-PD-1 antibody therapies.
On the regulatory front, BioXcel Therapeutics, Inc. (NASDAQ:BTAI) received FDA approval for its BXCL501, an investigational, proprietary, orally dissolving thin film formulation of dexmedetomidine for the treatment of...
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧